- Home
- THRD vs IIF Comparison
THRD vs IIF Comparison
Compare THRD & IIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THRD
- IIF
- Stock Information
- Founded
- THRD 2019
- IIF 1993
- Country
- THRD United States
- IIF United States
- Employees
- THRD N/A
- IIF N/A
- Industry
- THRD Biotechnology: Pharmaceutical Preparations
- IIF Trusts Except Educational Religious and Charitable
- Sector
- THRD Health Care
- IIF Finance
- Exchange
- THRD Nasdaq
- IIF Nasdaq
- Market Cap
- THRD 238.7M
- IIF 250.6M
- IPO Year
- THRD 2022
- IIF N/A
- Fundamental
- Price
- THRD $5.42
- IIF $27.73
- Analyst Decision
- THRD Hold
- IIF
- Analyst Count
- THRD 3
- IIF 0
- Target Price
- THRD $5.00
- IIF N/A
- AVG Volume (30 Days)
- THRD 251.2K
- IIF 45.4K
- Earning Date
- THRD 08-07-2025
- IIF 01-01-0001
- Dividend Yield
- THRD N/A
- IIF 13.94%
- EPS Growth
- THRD N/A
- IIF N/A
- EPS
- THRD N/A
- IIF N/A
- Revenue
- THRD N/A
- IIF N/A
- Revenue This Year
- THRD N/A
- IIF N/A
- Revenue Next Year
- THRD N/A
- IIF N/A
- P/E Ratio
- THRD N/A
- IIF N/A
- Revenue Growth
- THRD N/A
- IIF N/A
- 52 Week Low
- THRD $3.18
- IIF $18.95
- 52 Week High
- THRD $16.02
- IIF $24.41
- Technical
- Relative Strength Index (RSI)
- THRD 68.70
- IIF 62.70
- Support Level
- THRD $5.41
- IIF $26.96
- Resistance Level
- THRD $5.52
- IIF $27.37
- Average True Range (ATR)
- THRD 0.05
- IIF 0.30
- MACD
- THRD -0.01
- IIF -0.03
- Stochastic Oscillator
- THRD 64.29
- IIF 91.81
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
About IIF Morgan Stanley India Investment Fund Inc.
Morgan Stanley India Investment Fund, Inc. is the United States based non-diversified, closed-end management investment company. Its investment objective is to achieve long-term capital appreciation through investment in equity securities of Indian Issuers. The company's portfolio of investments consists of the investment in different sectors such as auto components, banks, capital markets, construction and engineering, pharmaceuticals and others.